Glycated hemoglobin and body mass index as mediators of GLP‐1RAs and Alzheimer's disease and related dementias in patients with type 2 diabetes
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with reductions in glycated hemoglobin (HbA1c) and body mass index (BMI) compared to other second-line glucose-lowering drugs(GLDs). GLP-1RA users were associated with a 26% lower risk of Alzheimer's disease and related dementias (ADRD) than other GLD users. The protective effect of GLP-1RAs against ADRD in adults with type 2 diabetes (T2D) is largely independent of their effects on HbA1c and BMI.
Authors
- William T. Donahoo (ORCID: https://orcid.org/0000-0002-2126-860X)
- Jiang Bian (ORCID: https://orcid.org/0000-0002-2238-5429)
- Yao An Lee (ORCID: https://orcid.org/0009-0008-3971-4242)
- Jingchuan Guo (ORCID: https://orcid.org/0000-0001-9799-2592)
- Mikael Svensson (ORCID: https://orcid.org/0000-0003-1179-7003)
- Huilin Tang (ORCID: https://orcid.org/0000-0002-5814-6657)
- Steven T. DeKosky (ORCID: https://orcid.org/0000-0003-3743-2758)
Institutions
- Center for Drug Evaluation and Research (US)
- University of Florida Health (US)
- University of Florida (US)
- Florida College (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/alz.70161
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47
Funders
- National Institutes of Health
- National Institute on Aging
- National Institute of Diabetes and Digestive and Kidney Diseases